Skip to main content
50°
Rain
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Latest News about ESALF
Recent news which mentions ESALF
< Previous
1
2
Next >
FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval
June 08, 2023
Tickers
BIIB
ESALF
ESALY
Tags
Market News
FDA
BIIB
From
Benzinga
Medicare unveils plan for coverage of new Alzheimer’s drugs
June 01, 2023
Tickers
BIIB
ESALF
LLY
Tags
ESALF
LLY
BIIB
From
MarketWatch
Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen
May 04, 2023
Tickers
BIIB
ESALF
ESALY
LLY
Tags
Expert Ideas
Biotech
Benzinga
From
Benzinga
Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes!
April 21, 2023
Tickers
BIIB
ESALF
ESALY
LLY
Tags
General
Briefs
Government
From
Benzinga
Merck, Eisai Shelve Keytruda Plus Lenvima Combo Trial In Skin Cancer Setting, Disappoints In Certain Type Of Colorectal Cancer
April 10, 2023
Tickers
ESALF
ESALY
MRK
Tags
Market News
MRK
General
From
Benzinga
National Institute on Aging Aims Building $300M Alzheimer's Research Database
April 03, 2023
Tickers
BIIB
ESALF
ESALY
Tags
Health Care
ESALF
Alzheimer’s
From
Benzinga
Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug
March 31, 2023
Tickers
BIIB
ESALF
ESALY
Tags
BIIB
General
Market News
From
Benzinga
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
March 16, 2023
Tickers
BIIB
ESALF
ESALY
LLY
Tags
General
Briefs
Government
From
Benzinga
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
March 14, 2023
Tickers
BIIB
ESALF
ESALY
Tags
Large Cap
News
Health Care
From
Benzinga
Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment
March 06, 2023
Tickers
BIIB
ESALF
ESALY
Tags
FDA
BIIB
General
From
Benzinga
The 7 Best Growth Stocks to Buy for February 2023
February 06, 2023
Tickers
ACLS
CPRX
DAR
ESALF
Tags
NOW
CPRX
Stocks to Buy
From
InvestorPlace
New Alzheimer’s drug shows some promise, but has big price tag
February 02, 2023
Tickers
BIIB
ESALF
Tags
JP:4523
BIIB
ESALF
From
MarketWatch
FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway
January 06, 2023
Tickers
BIIB
ESALF
ESALY
Tags
Briefs
Benzinga
ESALY
From
Benzinga
Biogen's Alzheimer's Antibody Might Have A Third Death Associated With
December 22, 2022
Tickers
BIIB
ESALF
ESALY
Tags
News
Large Cap
Briefs
From
Benzinga
Catalyst Pharma Acquires US Rights To Eisai's Epilepsy Drug
December 20, 2022
Tickers
CPRX
ESALF
ESALY
Tags
Movers
Biotech
Benzinga
From
Benzinga
Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate
November 30, 2022
Tickers
BIIB
ESALF
ESALY
Tags
Briefs
Biotech
Movers
From
Benzinga
Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's
November 30, 2022
Tickers
BIIB
ESALF
ESALY
Tags
Market News
BIIB
General
From
Benzinga
Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall
November 28, 2022
Tickers
BIIB
ESALF
ESALY
Tags
BIIB
why it's moving
Market News
From
Benzinga
One Alzheimer’s drug has failed, but investors are still betting on Biogen and Lilly treatments
November 14, 2022
Tickers
BIIB
ESALF
LLY
MOR
Tags
LLY
SPX
CH:ROG
From
MarketWatch
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
November 14, 2022
Tickers
BIIB
ESALF
ESALY
MOR
Tags
Small Cap
RHHVF
General
From
Benzinga
Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers
October 10, 2022
Tickers
BIIB
ESALF
ESALY
LLY
Tags
News
ESALF
Health Care
From
Benzinga
Medicare coverage of Eisai and Biogen’s promising new Alzheimer’s therapy is ‘another bridge to cross’
September 28, 2022
Tickers
BIIB
ESALF
SPX
Tags
ESALF
SPX
BIIB
From
MarketWatch
Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer
September 12, 2022
Tickers
ESALF
ESALY
MRK
Tags
Market News
General
MRK
From
Benzinga
Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate
August 25, 2022
Tickers
ESALF
ESALY
LLY
RHHBF
Tags
ESALF
LLY
Health Care
From
Benzinga
Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal
August 03, 2022
Tickers
ESALF
ESALY
MRK
Tags
Market News
MRK
General
From
Benzinga
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
July 06, 2022
Tickers
AMTI
BIIB
ESALF
ESALY
Tags
Market News
BIIB
RHHBY
From
Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Tickers
AGEN
ARWR
ATNX
AVGR
Tags
IMUX
Movers
FDA
From
Benzinga
Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug
May 10, 2022
Tickers
BIIB
ESALF
ESALY
Tags
ESALF
Alzheimer's disease
Benzinga
From
Benzinga
Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab
March 22, 2022
Tickers
BIIB
ESALF
ESALY
Tags
Phase 2 Trial
General
Biotech
From
Benzinga
FDA Approves Second Indication For Merck's Keytruda In Endometrial Cancer
March 22, 2022
Tickers
ESALF
ESALY
MRK
Tags
Market News
General
MRK
From
Benzinga
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.